Allergy Therapeutics plc has been mentioned in a Form 8.5 (EPT/RI) disclosure by Panmure Gordon (UK) Limited. The disclosure states that Panmure Gordon (UK) Limited, as an exempt principal trader, has made purchases and sales of Allergy Therapeutics' 0.1p ordinary shares. The disclosure provides details of the number of securities bought and sold, as well as the highest and lowest prices per unit paid or received.

The disclosure does not mention any cash-settled derivative transactions or stock-settled derivative transactions, including options, related to Allergy Therapeutics' securities. It also states that there are no indemnity or option arrangements, agreements, or understandings between Panmure Gordon (UK) Limited and any party to the offer or any person acting in concert with a party to the offer.

The contact person for the disclosure is Freddie Wooding, and the date of disclosure is September 26, 2023. The disclosure emphasizes that public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service, and the Panel's Market Surveillance Unit is available for consultation regarding the Code's dealing disclosure requirements.

No further information about Allergy Therapeutics or its operations is provided in the news.